News

Will Somerindyke founded Regulus Global a decade ago. Now, he’s raising hundreds of millions for ammunitions startup Union — and Regulus is the first customer.
VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Regulus Resources Inc. ("Regulus" or the "Company", TSX-V: REG, OTCQX: RGLSF) is pleased to provide an update on the Phase Two ...
Novartis NOVN0.23%increase; green up pointing triangle has agreed to acquire Regulus Therapeutics RGLS 0.38%increase; green up pointing triangle for a total equity value of up to roughly $1.7 ...
Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...
A high-level overview of Regulus Resources Inc. (RGLSF) stock. View (RGLSF) real-time stock price, chart, news, analysis, analyst reviews and more.
Regulus Therapeutics (RLS) contingent value right may be worth $3-$4 a share in its planned sale to Novartis (NVS), according to a Canaccord Genuity analyst. The analysis comes after Novartis (NGS ...
Mars and Regulus will move away from each other. Hence, the waxing crescent Moon will have space to appear between them, forming a beautiful conjunction. A that time, the Moon will be 4.7 days old.
Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease.
Explore Regulus Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RGLS.
Novartis has agreed to acquire Regulus Therapeutics for a total equity value of up to roughly $1.7 billion. With the merger, the Swiss pharmaceutical company aims to bring to more patients ...